UBS analyst David Dai initiated coverage of Iovance Biotherapeutics (IOVA) with a Buy rating and $17 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Iovance is “laser-focused” on manufacturing execution to drive near-term launch success for he first cell therapy in solid tumor, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio